Literature DB >> 20021703

The effect of a multispecies probiotic on the composition of the faecal microbiota and bowel habits in chronic obstructive pulmonary disease patients treated with antibiotics.

Catherina J M Koning1, Daisy Jonkers, Hauke Smidt, Frans Rombouts, Herman-Jan Pennings, Emiel Wouters, Ellen Stobberingh, Reinhold Stockbrügger.   

Abstract

Short-term antibiotic treatment profoundly affects the intestinal microbiota, which may lead to sustained changes in microbiota composition. Probiotics may restore such a disturbance. The objective of the present study was to investigate the effect of a multispecies probiotic on the faecal microbiota during and after antibiotic intake in patients with a history of frequent antibiotic use. In this randomised, placebo-controlled, double-blind study, thirty chronic obstructive pulmonary disease (COPD) patients treated with antibiotics for a respiratory tract infection received 5 g of a multispecies probiotic or placebo twice daily for 2 weeks. Faecal samples were collected at 0, 7, 14 and 63 d. Changes in the composition of the dominant faecal microbiota were determined by PCR-denaturing gradient gel electrophoresis (DGGE). Changes in bacterial subgroups were determined by quantitative PCR and culture. Bowel movements were scored daily according to the Bristol stool form scale. During and after antibiotic treatment, DGGE-based similarity indices (SI) were high ( >/= 84 %) and band richness was relatively low, both remaining stable over time. No difference in SI was observed between patients with and without diarrhoea-like bowel movements. The multispecies probiotic had a modest effect on the bacterial subgroups. Nevertheless, it affected neither the composition of the dominant faecal microbiota nor the occurrence of diarrhoea-like bowel movements. The dominant faecal microbiota was not affected by antibiotics in this COPD population, suggesting an existing imbalance of the microbiota, which may also have contributed to the lack of effect by probiotic intake.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20021703     DOI: 10.1017/S0007114509993497

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  7 in total

1.  Reliability and validity of a modified Bristol Stool Form Scale for children.

Authors:  Mariella M Lane; Danita I Czyzewski; Bruno P Chumpitazi; Robert J Shulman
Journal:  J Pediatr       Date:  2011-04-13       Impact factor: 4.406

2.  In-vitro antibacterial activity of commercially available probiotics on food-borne pathogens along with their synergistic effects with synthetic drugs.

Authors:  Mrityunjoy Acharjee; Fhamida Hasan; Tamanna Islam; Ifra Tun Nur; Nila Begum; Chayanika Mazumder; Mahabuba Akter Lubna; Nagma Zerin; Asif Shahriar; Md Rayhan Mahmud
Journal:  Metabol Open       Date:  2022-05-21

3.  Intestinal microbiota in human health and disease: the impact of probiotics.

Authors:  Jacoline Gerritsen; Hauke Smidt; Ger T Rijkers; Willem M de Vos
Journal:  Genes Nutr       Date:  2011-05-27       Impact factor: 5.523

4.  Defining microbiota for developing new probiotics.

Authors:  Maria Carmen Collado; Christine Bäuerl; Gaspar Pérez-Martínez
Journal:  Microb Ecol Health Dis       Date:  2012-06-18

5.  Effect of a multispecies probiotic on reducing the incidence of antibiotic-associated diarrhoea in children: a protocol for a randomised controlled trial.

Authors:  Jan Łukasik; Hania Szajewska
Journal:  BMJ Open       Date:  2018-06-04       Impact factor: 2.692

Review 6.  A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands.

Authors:  Valeria Agamennone; Cyrille A M Krul; Ger Rijkers; Remco Kort
Journal:  BMC Gastroenterol       Date:  2018-08-06       Impact factor: 3.067

Review 7.  The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases.

Authors:  Dapeng Zhang; Sha Li; Ning Wang; Hor-Yue Tan; Zhimin Zhang; Yibin Feng
Journal:  Front Microbiol       Date:  2020-02-25       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.